Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue ...

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

Fintel reports that on December 17, 2024, B of A Securities downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Buy to ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding ...

According to Benzinga Pro, Exelixis's peer group average for short interest as a percentage of float is 4.93%, which means ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and ...

As previously reported, BofA downgraded Exelixis (EXEL) to Neutral from Buy with a price target of $39, up from $35. The stock price has gained ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.

Brookline initiated coverage of Exelixis (EXEL) with a Buy rating.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top ...